V A Georgoulias

Summary

Country: Greece

Publications

  1. ncbi request reprint A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
    D Mavroudis
    Department of Medical Oncology, School of Medicine, University of Crete, Greece
    Ann Oncol 12:463-70. 2001
  2. ncbi request reprint A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors
    S Kakolyris
    Department of Clinical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Oncology 61:265-70. 2001
  3. ncbi request reprint Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, PO Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 34:S71-6. 2001
  4. ncbi request reprint Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer
    V A Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Oncology (Williston Park) 15:18-24. 2001
  5. ncbi request reprint A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Greece
    Lung Cancer 30:193-8. 2000
  6. ncbi request reprint Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 11:1249-54. 2000
  7. ncbi request reprint Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 11:757-60. 2000
  8. ncbi request reprint Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion 71110, Crete, Greece
    Lung Cancer 32:179-87. 2001
  9. pmc Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
    V Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Br J Cancer 91:482-8. 2004
  10. ncbi request reprint Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study
    D Mavroudis
    Department of Medical Oncology, School of Medicine, University of Crete, University General Hospital of Iraklion, 71110 Iraklion, Crete, Greece
    Lung Cancer 38:59-63. 2002

Collaborators

Detail Information

Publications63

  1. ncbi request reprint A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
    D Mavroudis
    Department of Medical Oncology, School of Medicine, University of Crete, Greece
    Ann Oncol 12:463-70. 2001
    ..In order to compare the TEP combination to cisplatin etoposide (EP) regimen as front-line treatment in patients with SCLC, we conducted a randomised multicenter study...
  2. ncbi request reprint A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors
    S Kakolyris
    Department of Clinical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Oncology 61:265-70. 2001
    ..We conducted a phase I study to evaluate the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of topotecan given in a novel schedule of administration in patients with refractory solid tumors...
  3. ncbi request reprint Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, PO Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 34:S71-6. 2001
    ..The combination of CPT-11 and P is a safe, well-tolerated, and active regimen for the treatment of patients with advanced NSCLC previously treated with a docetaxel-based front-line regimen...
  4. ncbi request reprint Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer
    V A Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Oncology (Williston Park) 15:18-24. 2001
    ..Furthermore, the combination should be compared with other more standard or investigational regimens...
  5. ncbi request reprint A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Greece
    Lung Cancer 30:193-8. 2000
    ..A phase I study was conducted to determine the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of a CPT-11 plus cisplatin combination as salvage treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  6. ncbi request reprint Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 11:1249-54. 2000
    ..We conducted a multicenter phase II study to evaluate the efficacy and tolerability of this regimen as front-line treatment in women with advanced breast cancer (ABC)...
  7. ncbi request reprint Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 11:757-60. 2000
    ....
  8. ncbi request reprint Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion 71110, Crete, Greece
    Lung Cancer 32:179-87. 2001
    ....
  9. pmc Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
    V Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Br J Cancer 91:482-8. 2004
    ..CPT-11+gemcitabine resulted in a higher response rate and better control of disease-related symptoms than CPT-11 alone, but without any improvement in the overall survival...
  10. ncbi request reprint Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study
    D Mavroudis
    Department of Medical Oncology, School of Medicine, University of Crete, University General Hospital of Iraklion, 71110 Iraklion, Crete, Greece
    Lung Cancer 38:59-63. 2002
    ..In order to investigate the feasibility of a potentially non-cross resistant drug regimen, we alternated cycles of cisplatin-etoposide with topotecan as front-line treatment in patients with extensive stage small cell lung cancer (SCLC)...
  11. ncbi request reprint Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Alexandroupolis, Crete, Greece
    Oncology 66:253-9. 2004
    ..A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of their combination in patients with refractory solid tumors...
  12. ncbi request reprint Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
    Lung Cancer 53:59-65. 2006
    ..To evaluate the efficacy and tolerance of a cisplatin plus etoposide regimen followed by thoracic radiotherapy (TRT) and paclitaxel plus cisplatin consolidation chemotherapy in patients with limited stage small cell lung cancer (SCLC)...
  13. ncbi request reprint A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
    S Agelaki
    Department of Medical Oncology, University General Hospital of Herakijon, Crete, Greece
    Lung Cancer 34:133-9. 2001
    ..CONCLUSIONS: The combination of topotecan 0.90 mg/m(2) on days 1-5, with epirubicin 40 mg/m(2) on day 8, administered every 28 days is a feasible outpatient regimen which merits further evaluation in patients with chemosensitive disease...
  14. ncbi request reprint Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, GR 71110 Heraklion, Crete, Greece
    Oncology 64:207-12. 2003
    ..To evaluate the efficacy and safety of docetaxel in combination with carboplatin as salvage treatment in women with metastatic breast cancer (MBC)...
  15. ncbi request reprint Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study
    S Kakolyris
    Department of Clinical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 12:193-7. 2001
    ..CONCLUSIONS: The combination of paclitaxel and carboplatin is a relatively active and well-tolerated regimen as salvage treatment in patients with refractory SCLC...
  16. ncbi request reprint Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Oncology 67:250-6. 2004
    ..To evaluate the docetaxel-gemcitabine combination administered every 2 weeks in women with untreated metastatic breast cancer (MBC)...
  17. ncbi request reprint Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece
    N Maniadakis
    Department of Medical Oncology, University General Hospital of Heraklion, Voutes 71110, Crete, Greece
    Lung Cancer 58:275-81. 2007
    ....
  18. ncbi request reprint A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 63:213-8. 2002
    ..A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of their combination in patients with refractory solid tumors...
  19. pmc Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
    M I Koukourakis
    Department of Radiotherapy and Oncology, University Hospital of Heraklion, Crete, Greece
    Br J Cancer 80:1792-6. 1999
    ..Further trials with docetaxel-based radiochemotherapy should integrate accelerated radiotherapy together with cytoprotection...
  20. doi request reprint Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    D Mavroudis
    Department of Medical Oncology, University Hospital of Heraklion, 71110 Heraklion, PO Box 1352, Crete, Greece
    Ann Oncol 21:48-54. 2010
    ..The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer (ABC)...
  21. pmc Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study
    V Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Br J Cancer 93:763-9. 2005
    ..The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate...
  22. ncbi request reprint Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer
    V Georgoulias
    University General Hospital of Iraklion, Crete, Greece
    Semin Oncol 28:15-21. 2001
    ..Docetaxel combined with other new agents, particularly gemcitabine, may offer another useful alternative to cisplatin-based chemotherapy in patients with good performance status...
  23. ncbi request reprint Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial
    V Georgoulias
    University Hospital of Heraklion, Crete, Greece
    Lung Cancer 34:S47-51. 2001
    ..The toxicity profile of the DG combination was relatively milder. Hence, cisplatin cannot be considered longer as a mandatory component of chemotherapy against NSCLC...
  24. doi request reprint Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 62:356-63. 2008
    ..One of its more common side effects is neutropenia. The association between the grade of DG-induced neutropenia and the clinical outcome was analyzed...
  25. pmc Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracyclin
    K Kalbakis
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, P O Box 1352, 71110, Heraklion, Crete, Greece
    Br J Cancer 85:798-802. 2001
    ..The combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well tolerated and effective salvage regimen in patients with MBC heavily pretreated with both anthracyclines and taxanes...
  26. ncbi request reprint Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study
    P Makrantonakis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, 71100 Heraklion, Crete, Greece
    Lung Cancer 53:85-90. 2006
    ..To assess the efficacy and tolerance of the vinorelbine/cisplatin combination in non-small cell lung cancer patients pre-treated with a taxane-based regimen...
  27. ncbi request reprint A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors
    A Karampeazis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Oncology 71:347-53. 2006
    ..To determine the maximum tolerated doses (MTDs) and the dose-limiting toxicities of a biweekly administration of oral vinorelbine and gemcitabine in patients with advanced solid tumors...
  28. doi request reprint Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
    Oncology 74:31-6. 2008
    ....
  29. ncbi request reprint Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case
    G E Chalkiadakis
    Department of General Surgery, University General Hospital of Heraklion, University of Crete, Heraklion, Crete, Greece
    Int J Gynecol Cancer 15:1115-9. 2005
    ..Ovarian cancer with concomitant extensive right colon infiltration and hematogenous liver metastases can be successfully managed with aggressive surgical resection and postoperative chemotherapy in carefully selected patients...
  30. doi request reprint Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study
    N Xenidis
    Department of Medical Oncology, University General Hospital of Alexandroupolis, Greece
    Lung Cancer 68:450-4. 2010
    ..We conducted a phase II study to evaluate the efficacy and tolerance of EP regimen followed by thoracic radiotherapy (TRT) and IP consolidation chemotherapy in patients with limited-stage small cell lung cancer...
  31. pmc A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
    V Bozionelou
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Br J Cancer 97:43-9. 2007
    ..The PK data revealed no obvious drug interactions. Biweekly administration of PLD, PCX and GEM is a well-tolerated chemotherapy regimen, which merits further evaluation in various types of solid tumours...
  32. ncbi request reprint Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy
    J Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Ann Oncol 18:305-10. 2007
    ..Thirty-one (77.5%) and nine (22.5%) patients had oxaliplatin-refractory and -resistant disease, respectively; in addition, 32 (80%) patients had also progressed on prior irinotecan-based chemotherapy...
  33. doi request reprint Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
    A Valachis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Breast Cancer Res Treat 122:1-7. 2010
    ..Bevacizumab treatment might be suggested for treatment of 1st line metastatic breast cancer, but more data are needed until statistical overall survival differences will be documented and firm guideline recommendation could be given...
  34. ncbi request reprint A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 14:304-12. 2003
    ..We conducted a phase I study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the combination in patients with advanced solid tumors...
  35. ncbi request reprint Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study
    S Kakolyris
    Department of Medical Oncology, University General Hospital, Alexandroupolis, Greece
    Oncology 70:273-9. 2006
    ..It was the aim of this study to evaluate the activity and tolerance of gemcitabine and oxaliplatin in pretreated metastatic breast cancer patients...
  36. ncbi request reprint Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 55:101-7. 2007
    ..To evaluate the activity and toxicity of the sequential administration of docetaxel followed by gefitinib in patients with advanced non-small cell lung cancer (NSCLC)...
  37. ncbi request reprint Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial
    J Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Dig Dis 25:100-5. 2007
    ..A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer...
  38. ncbi request reprint Transient fungemia due to Rhodotorula rubra in a cancer patient: case report and review of the literature
    G Samonis
    Division of Medicine, The University of Crete, Greece
    Infection 29:173-6. 2001
    ..Restoration of the patient's defense mechanisms was adequate for disappearance of the fungus from the patient's blood and full recovery...
  39. ncbi request reprint Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial
    V Georgoulias
    Department of Medical Oncology, School of Medicine, University of Crete, Heraklion, Greece
    J Clin Oncol 17:914-20. 1999
    ..To evaluate the tolerance and efficacy of the combination of docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC)...
  40. ncbi request reprint Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
    V Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, POBox 1352, Heraklion 71110, Crete, Greece
    Lancet 357:1478-84. 2001
    ....
  41. ncbi request reprint Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study
    D Mavroudis
    Department of Medical Oncology, School of Medicine, University of Crete, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete 71110, Greece
    Lung Cancer 39:71-6. 2003
    ..To evaluate the activity of the sequential administration of cisplatin-etoposide (PE) followed by topotecan (TOP) in patients with extensive stage small cell lung cancer (SCLC)...
  42. ncbi request reprint Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials
    S Agelaki
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Oncology 60:235-41. 2001
    ..Stabilization of disease was associated with a favorable survival in both studies...
  43. ncbi request reprint Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer
    M I Koukourakis
    Department of Radiotherapy and Oncology, University Hospital of Heraklion, Iraklion, Crete, Greece
    Med Oncol 17:135-43. 2000
    ..Broad spectrum cytoprotection with amifostine and GM-CSF may also contribute to the reduction of incidence of neurosensory reactions and asthenia in patients treated with taxanes...
  44. ncbi request reprint A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors
    C Kouroussis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Am J Clin Oncol 24:404-7. 2001
    ..The weekly administration of paclitaxel for 4 consecutive weeks in cycles of 6 weeks is a feasible, safe, and active outpatient regimen that merits further evaluation in combination with other anticancer agents...
  45. ncbi request reprint Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer
    S Kakolyris
    Department of Clinical Oncology, University General Hospital of Heraklion, Heraklion 71110, Crete, Greece
    Clin Cancer Res 7:3087-91. 2001
    ..High TRX mRNA levels have been found in lung carcinomas, a trait associated with a growth and survival advantage...
  46. ncbi request reprint Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Oncology 62:216-22. 2002
    ..We conducted a phase I study to determine the maximum tolerated doses (MTD) and the dose limiting toxicities (DLT) of the combination administered every 2 weeks in patients with advanced solid tumors...
  47. ncbi request reprint Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study
    S Agelaki
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 71110, Crete, Greece
    Lung Cancer 34:S77-80. 2001
    ....
  48. ncbi request reprint Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial
    J Souglakos
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Crete
    J Clin Oncol 20:2651-7. 2002
    ..To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)...
  49. ncbi request reprint ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program
    A G Pallis
    Department of Medical Oncology, University Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 40:301-7. 2003
    ....
  50. pmc Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
    J Souglakos
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece
    Br J Cancer 98:1710-5. 2008
    ..Prospective studies are warranted to evaluate the role of these markers in tailoring chemotherapy...
  51. ncbi request reprint Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours
    N Androulakis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Crete, Greece
    Eur J Cancer 38:1992-7. 2002
    ....
  52. ncbi request reprint Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan
    N Ziras
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Oncology 70:106-14. 2006
    ....
  53. ncbi request reprint Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
    J Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete
    Ann Oncol 15:1204-9. 2004
    ..The purpose of this study was to evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) as first-line treatment in patients with locally advanced or metastatic gastric cancer (AGC)...
  54. pmc FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    J Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete 71110, Greece
    Br J Cancer 94:798-805. 2006
    ..The present study failed to demonstrate any superiority of the FOLFOXIRI combination compared with the FOLFIRI regimen, although the observed median OS is one of the best ever reported in the literature...
  55. ncbi request reprint Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study
    C Kouroussis
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Greece
    Oncology 61:36-41. 2001
    ..CONCLUSIONS: The bimonthly administration of L-OHP in association with LV-modulated bolus plus infusional 5-FU ('de Gramont' regimen) is a well-tolerated and effective front-line treatment for metastatic CRC...
  56. ncbi request reprint A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors
    A Kalykaki
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 71:197-203. 2006
    ..The study aimed to determine the maximum tolerated doses (MTDs) and identify the dose-limiting toxicities of the biweekly administration of pemetrexed plus gemcitabine in patients with solid tumors...
  57. ncbi request reprint Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer
    M I Koukourakis
    Department of Radiotherapy Oncology, University Hospital of Iraklion, Crete, Greece
    Cancer Res 60:3088-95. 2000
    ..Clinical trials involving targeting of the VEGF/KDR-positive vasculature with specific antibodies, such as 11B5, are, therefore, encouraged...
  58. pmc Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    A Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 99:923-9. 2008
    ....
  59. ncbi request reprint A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer
    S Kakolyris
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 60:207-13. 2001
    ..CONCLUSIONS: The combination of a 4-day continuous infusion of 5-FU followed by CPT-11 represents an active and well-tolerated regimen for patients with colorectal cancer. This regimen merits further evaluation in phase II studies...
  60. ncbi request reprint Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer
    N Xenidis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 14:849-55. 2003
    ....
  61. ncbi request reprint Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study
    L Vamvakas
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion 71110, Crete, Greece
    Am J Clin Oncol 25:65-70. 2002
    ..Final results from large phase III trials are awaited to clarify whether the CPT-11/5-FU combinations should be considered as "standard" first-line treatment in ACC...
  62. ncbi request reprint Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract
    I Gkioulbasanis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    J BUON 12:197-202. 2007
    ....
  63. pmc 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Br J Cancer 97:1560-6. 2007
    ..The clinical relevance of 'other' EGFR mutation variants remains uncertain and requires further assessment in a prospective study...